Bibliography
- Institute of Medicine of the National Academies. Introduction. In: Field MJ, Boat TF, editors. Rare diseases. and orphan products: accelerating research and development. The National Academies Press, Washington, DC; 2010
- Orphan Drug Act, Pub. L. 97-414. 96 Stat. 2049, 1983. Amended in 1984 by Pub. L. 98-551 to add a numeric prevalence threshold to the definition of rare diseases
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions – E1. 1994. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf [Accessed 8 January 2014]
- US Food and Drug Administration. Drug@FDA. FDA Approved Drug Products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 8 January 2014]
- US Food and Drug Administration. MedWatch. The FDA safety information and adverse event reporting program safety information. Available from: http://www.fda.gov/Safety/MedWatch/default.htm [Accessed 8 January 2014]
- Code of Federal Regulations Title 21: specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1). Pt 201.57. 2013
- Shieppati A, Henter J, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008;371:2039-41
- Remuzzi G, Garattini S. Rare diseases: what’s next? Lancet 2008;371:1978-9
- Braun MM, Farag-El-Massah S, Xu K, Cote T. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9:519-22
- Committee for Orphan Medicinal Products and the European Medicines. Westermark K, Holm BB, Söderholm M, et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 2011;10:341-9
- US Food and Drug Administration. Guidance for industry: expedited programs for serious conditions – drugs and biologics [draft guidance]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf [Accessed 3 April 2014]
- Sasinowski FJ. Quantum of effectiveness evidence in FDA’s approval of orphan drugs. Drug Inf J 2012;46:238-63
- Pariser AR, Slack DJ, Bauer LJ, et al. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010. Drug Discov Today 2012;17:898-904
- Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs. non-orphan drugs for cancer. JAMA 2011;305:2320-6
- Mitsumoto J, Dorsey ER, Beck CA, et al. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009;66:184-90
- Downing NS, Aminawang JA, Shah ND, et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014;311:368-77
- US Food and Drug Administration. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/default.htm [Accessed 23 January 2014]
- FDA Approval Letter NDA 203469/S-007 & S-008. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/203469Orig1s007,s008ltr.pdf [Accessed 23 January 2014]
- Prasad V, Mailankody S. The accelerated approval of oncologic drugs. Lessons from ponatinib. JAMA 2014;311:353-4
- US Food and Drug Administration. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070256.htm [Accessed 13 March 2014]
- Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, et al. Safety-related regulatory actions for Orphan drugs in the US and EU. Drug Saf 2010;33:127-37
- Duijnhoven RG, Straus SM, Raine JM, et al. Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med 2010;10:e1001407
- Moore TJ, Singh S, Furberg CD. The FDA and new safety warnings. Arch Intern Med 2012;172:78-80
- Lester J, Neyarapally GA, Lipowski E, et al. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf 2013;22:302-5
- Mol PG, Straus SM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf 2010;33:463-74
- Joppi R, Bertele V, Garattini S. Orphan drug development is not taking off. Br J Clin Pharmacol 2009;67:494-502
- Code of Federal Regulations Title 21: Approval of an application and an abbreviated application, Sec. 314.105
- Kesselheim AS, Gagne JJ. Strategies for post-market surveillance of drugs for rare diseases. Clin Pharmacol Ther 2014;95:265-8
- National Institutes of Health. The Office of Rare Diseases Research Global Rare Diseases Patient Registry and Data Repository. Available from: https://grdr.ncats.nih.gov [Accessed 10 March 2014]
- Code of Federal Regulations Title 21: Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses, Sec. 312.80 Subpart E